A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
A phase 3 trial testing UGN-104 in bladder & urothelial cancer, now recruiting.
Overview
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer is a phase 3 interventional study registered as NCT06774131, led by UroGen Pharma, and recruiting when checked on 2026-09-11. Official title: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC). Planned enrolment is 70 participants (estimated). The study started in 2025-08-06 and primary completion is expected in 2027-03. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
Shares UroGen Pharma, Bladder & urothelial cancer and the tag ctgov-ingest.
- TreatmentUGN-103
Shares UroGen Pharma, Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Shares Bladder & urothelial cancer and the tag ctgov-ingest.